Enhancing Domestic Drug Manufacturing Competitiveness Act

This bill tells the Government Accountability Office (GAO) to study what rules and red tape make it hard or slow to build or expand drug manufacturing plants in the United States. The study must also compare U.S. rules to those in other countries, look at how these rules affect the drug supply chain, and suggest steps regulators could take—like speeding up reviews and inspections—to fix the problems. The GAO has to report the results to Congress within one year after the law takes effect .

The GAO must talk with industry and other stakeholders, check if new technologies or manufacturing methods could help, and recommend ways to streamline rules so more medicine can be made in the U.S..

• Who is affected: GAO, federal regulators, and drug manufacturers; indirectly, patients and communities where plants might be built.
• What changes: A one-time study to identify barriers, compare with other countries, and recommend fixes and tech solutions; possible ideas include faster reviews, inspections, and approvals for facilities .
• When: The report is due within 1 year after the law is enacted.